Patent US3819567A successfully refreshed from Google Patents.
US4929639A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Oxygen-containing heterocyclic compound
Assignee: Astellas Pharma Inc
•
Filing: 1988-06-20
•
Granted: 1990-05-29
•
Expires: 2008-06-20
Abstract
Abstract The invention relates to treatment of diseases caused by thromboxane A 2 comprising administering a compound ##STR1## wherein R 1 is hydrogen or lower alkyl, R 2 is carboxy(lower)alkyl or protected carboxy(lower)alkyl and R 3 is --CH═N--R 4 in which R 4 is arylureido or arylthioureido and X is --O--, or a pharmaceutically acceptable salt thereof.
Inventors
- 👤 Hiroyuki Setoi
- 👤 Akio Kuroda
- 👤 Hirokazu Tanaka
- 👤 Hideo Hirai
- 👤 Hiroshi Marusawa
- 👤 Masashi Hashimoto
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 05:27
CPC Classifications
C; C07; C07D; C07D405/00; C07D405/02; C07D405/12; A; A61; A61P; A61P7/00; A61P7/02; C07D309/00; C07D309/02; C07D309/04; C07D309/06; C07D319/00; C07D319/04; C07D319/06; C07D409/00; C07D409/02; C07D409/12
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
44 words
A compound of the formula: ##STR38## wherein R 1 is hydrogen or lower alkyl, R 2 is carboxy(lower)alkyl or protected carboxy(lower)alkyl and R 3 is --CH═N--R 4 in which R 4 is arylureido or arylthioureido and X is --O--, or pharmaceutically acceptable salt thereof.
Claim 2
Dependent Claim
44 words
A compound of the formula: ##STR38## wherein R 1 is hydrogen or lower alkyl, R 2 is carboxy(lower)alkyl or protected carboxy(lower)alkyl and R 3 is --CH═N--R 4 in which R 4 is arylureido or arylthioureido and X is --O--, or pharmaceutically acceptable salt thereof.
Claim 3
Dependent Claim
14 words
The compound of claim 1, in which R 2 is carboxy)lower)alkyl or lower alkoxycarbonyl(lower)alkyl.
Claim 4
Dependent Claim
13 words
The compound of claim 2, in which R 4 is phenylureido or phenylthioureido.
Claim 5
Dependent Claim
20 words
The compound of claim 3, in which R 1 is hydrogen or methyl, and R 2 is carboxypropyl or methoxycarbonylpropyl
Claim 6
Dependent Claim
17 words
The compound of claim 1, in which R 1 is lower alkyl, and R 2 is carboxy(lower)alkyl
Claim 7
Dependent Claim
14 words
The compound of claim 5, which is (2R,4R,5S)-5-[(z)-6- carboxy-2-hexenyl]-2-methyl-4-(4-phenylsemicarbazonomethyl)-1,3-dioxane or pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
13 words
The compound of claim 5, which is 2R,4R,5S)-5-[(z)-6-carboxy-2-hexanyl]-2-methyl-4-[4-(phenyl)thiosemicarbazonomethyl]-1,3-dioxane or pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim
60 words
A thromboxane A 2 -antagonist pharmaceutical composition comprising an effective amount of a compound of the formula: ##STR39## wherein R 1 is hydrogen or lower alkyl, R 2 is carboxy(lower)alkyl or protected carboxy(lower)alkyl and R 3 is --CH═N--R 4 in which R 4 is arylureido or arylthioureido and X is --O--, or pharmaceutically acceptable salt thereof and pharmaceutically acceptable carrier.
Claim 10
Dependent Claim
60 words
A thromboxane A 2 -antagonist pharmaceutical composition comprising an effective amount of a compound of the formula: ##STR39## wherein R 1 is hydrogen or lower alkyl, R 2 is carboxy(lower)alkyl or protected carboxy(lower)alkyl and R 3 is --CH═N--R 4 in which R 4 is arylureido or arylthioureido and X is --O--, or pharmaceutically acceptable salt thereof and pharmaceutically acceptable carrier.
Claim 11
Independent Claim
64 words
A method for treatment of diseases caused by thromboxane A 2 which comprises administering to a human or animal an effective amount of a compound ##STR40## wherein R 1 is hydrogen or lower alkyl, R 2 is carboxy(lower)alkyl or protected carboxy(lower)alkyl and R 3 is --CH═N--R 4 in which R 4 is arylureido or arylthioureido and X is --O--, or pharmaceutically acceptable salt thereof.
Claim 12
Independent Claim
64 words
A method for treatment of diseases caused by thromboxane A 2 which comprises administering to a human or animal an effective amount of a compound ##STR40## wherein R 1 is hydrogen or lower alkyl, R 2 is carboxy(lower)alkyl or protected carboxy(lower)alkyl and R 3 is --CH═N--R 4 in which R 4 is arylureido or arylthioureido and X is --O--, or pharmaceutically acceptable salt thereof.
References Cited (Backward Citations)
FR2451374A1
Cited
US4567197A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-05-28 | 1993-11-27 | 1994-05-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-05-28 | 1997-11-27 | 1998-05-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-05-28 | 2001-11-27 | 2002-05-29 | $7700.00 | Window Closed / Lapsed |